Veröffentlichungen

Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals

S. Denker
A. Bittner
M. Frick
J. Kase
J. Hoffmann
C. Trenker
U. Keller
C. Bogner
A. Hüttmann
J. Dürig
M. Janz
S. Mathas
R. Marks
U. Krohn
I.K. Na
L. Bullinger
C.A. Schmitt

Aberrant expression of and cell death induction by engagement of the MHC-II chaperone CD74 in anaplastic large cell lymphoma (ALCL)

K.D. Wurster
M. Costanza
S. Kreher
S. Glaser
B. Lamprecht
N. Schleussner
I. Anagnostopoulos
M. Hummel
K. Jöhrens
H. Stein
A. Molina
A. Diepstra
B. Gillissen
K. Köchert
R. Siebert
O. Merkel
L. Kenner
M. Janz
S. Mathas

22. September 2021 in Nat Commun

Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma

H.C. Liang
M. Costanza
N. Prutsch
M.W. Zimmerman
E. Gurnhofer
I.A. Montes-Mojarro
B.J. Abraham
N. Prokoph
S. Stoiber
S. Tangermann
C. Lobello
J. Oppelt
I. Anagnostopoulos
T. Hielscher
S. Pervez
W. Klapper
F. Zammarchi
D.A. Silva
K.C. Garcia
D. Baker
M. Janz
N. Schleussner
F. Fend
Š. Pospíšilová
A. Janiková
J. Wallwitz
D. Stoiber
I. Simonitsch-Klupp
L. Cerroni
S. Pileri
L. de Leval
D. Sibon
V. Fataccioli
P. Gaulard
C. Assaf
F. Knörr
C. Damm-Welk
W. Woessmann
S.D. Turner
A.T. Look
S. Mathas
L. Kenner
O. Merkel

Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group

C. Damaschin
H. Goergen
S. Kreissl
A. Plütschow
F. Breywisch
S. Mathas
J. Meissner
M. Sökler
M.S. Topp
V. Vucinic
A. Zimmermann
B. von Tresckow
M. Fuchs
A. Engert
P. Borchmann
D.A. Eichenauer

High-dose glucocorticoid treatment of near-fatal Bocavirus lung infection results in rapid recovery

M. Obenaus
O. Schildgen
D. Schürmann
A.C. von Brünneck
M. Janz
U. Keller
B. Gebauer
J. Schilling
S. Schwartz
B. Weissbrich
T. Schneider
J. Hofmann
S. Mathas

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1

S. Reinke
P.J. Bröckelmann
I. Iaccarino
M. Garcia-Marquez
S. Borchmann
F. Jochims
M. Kotrova
K. Pal
M. Brüggemann
E. Hartmann
S. Sasse
C. Kobe
S. Mathas
M. Soekler
U. Keller
M. Bormann
A. Zimmermann
J. Richter
M. Fuchs
B. von Tresckow
P. Borchmann
H. Schlößer
M. von Bergwelt-Baildon
A. Rosenwald
A. Engert
W. Klapper

Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial

P.J. Bröckelmann
H. Goergen
U. Keller
J. Meissner
R. Ordemann
T.V. Halbsguth
S. Sasse
M. Sökler
A. Kerkhoff
S. Mathas
A. Hüttmann
M. Bormann
A. Zimmermann
J. Mettler
M. Fuchs
B. von Tresckow
C. Baues
A. Rosenwald
W. Klapper
C. Kobe
P. Borchmann
A. Engert

Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma

B. Edginton-White
P. Cauchy
S.A. Assi
S. Hartmann
A.G. Riggs
S. Mathas
P.N. Cockerill
C. Bonifer

Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma

L. von Hoff
E. Kärgel
V. Franke
E. McShane
K.W. Schulz-Beiss
G. Patone
N. Schleussner
M. Kolesnichenko
N. Hübner
O. Daumke
M. Selbach
A. Akalin
S. Mathas
C. Scheidereit

The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma

N. Schleussner
O. Merkel
M. Costanza
H.C. Liang
F. Hummel
C. Romagnani
P. Durek
I. Anagnostopoulos
M. Hummel
K. Jöhrens
A. Niedobitek
P.R. Griffin
R. Piva
H.L. Sczakiel
W. Woessmann
C. Damm-Welk
C. Hinze
D. Stoiber
B. Gillissen
S.D. Turner
E. Kaergel
L. von Hoff
M. Grau
G. Lenz
B. Dörken
C. Scheidereit
L. Kenner
M. Janz
S. Mathas